Xcout Intel
MSICS Pharma competitors & alternatives
The 12 closest competitors and alternatives to MSICS Pharma among pharmaceuticals companies — ranked by similarity to what MSICS Pharma actually does, not by market-cap band.
Subscribe to see MSICS Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About MSICS Pharma
MSICS Pharma is an Israeli pharmaceutical startup founded in 2022 and headquartered in Ness Ziona. The company develops technology for growing and producing medical-grade psilocybin for pharmaceutical use and is advancing clinical trials for conditions such as PTSD, depression, and OCD.
MSICS Pharma at a glance
MSICS Pharma is a pharmaceuticals company headquartered in Israel. Its most recent funding round, Series A, raised $3.6M in May 2026. Xcout tracks 2 named people at MSICS Pharma, including Roei Zerahia (CEO).
MSICS Pharma leadership
- Roei ZerahiaCEO
- Omer ZerahiaCBO
MSICS Pharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $3.6M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 MSICS Pharma competitors
Ranked by semantic similarity — how close each company is to MSICS Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Pharma Two B Ltd. is a late-clinical stage biopharmaceutical company headquartered in Kiryat Ono, Israel. The company focuses on developing pharmaceutical treatments and therapeutic products for neurological and related medical conditions. It has pursued corporate growth initiatives, including planned public market transactions via mergers.
Similar pharmaceuticals company
Abital Pharma Pipelines is an incubator in Israel dedicated to advancing life science innovation. The company collaborates with the Naiot incubator to develop drugs targeting the central nervous system.
Similar pharmaceuticals company
Mindset Pharma Inc. is a drug discovery and development company based in Toronto, Canada, focused on creating optimized, patentable next-generation psychedelic medicines.
Similar pharmaceuticals company
Mapi Pharma is an Israeli pharmaceutical company that develops complex generic and proprietary drug products, with a focus on long-acting injectable formulations. Its products are intended for patients and healthcare providers, and the company works with pharmaceutical partners to develop and commercialize treatments, including therapies for neurological conditions such as multiple sclerosis.
Pharmaceuticals, Biotechnology & Life Sciences
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
Similar pharmaceuticals company
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Similar pharmaceuticals company
Abital Pharma is an Israeli therapeutics company founded in 2012 by Prof. Moussa B. H. Youdim, focusing on the development of original drugs and operating as a life science incubator.
Similar pharmaceuticals company
BetterLife Pharma Inc., a biotechnology firm headquartered in Vancouver, Canada, specializes in researching and bringing to market therapeutic compounds designed to address neurological disorders across the globe. The company's core focus involves refining and advancing drug candidates derived from interferon-based technologies, which are intended to leverage the immune system to combat viral infections. Its diverse product pipeline includes BETR-001, targeting conditions such as major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another candidate, BETR-002, is being developed for benzodiazepine dependency, anxiety, and spasticity. Furthermore, BetterLife Pharma is working on MM-003 for COVID-19 and other respiratory viral infections, MM-001 as a localized intravaginal cream for HPV-induced cervical intraepithelial neoplasia, and AP-002 for cancer treatment. The company also maintains a research collaboration with the University of California San Diego, conducting preclinical behavioral pharmacology studies on TD-0148A, a lysergic acid diethylamide derivative solution. Incorporated in 2002, the company operated as Pivot Pharmaceuticals Inc. before officially changing its name to BetterLife Pharma Inc. in December 2019.
Similar pharmaceuticals company
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Similar pharmaceuticals company
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Hod Hasharon, Israel. The company focuses on the development and commercialization of treatments for ophthalmic and other serious medical conditions.
Similar pharmaceuticals company
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.
Similar pharmaceuticals company
AtaiBeckley is a biotechnology company focused on the development of psychedelic drugs. The company has been the subject of an acquisition agreement by Eli Lilly to expand its neuroscience pipeline.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of MSICS Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for MSICS Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →